| Literature DB >> 34768793 |
Xiumei Luo1,2,3, Wenxian Wu1, Li Feng1, Haim Treves4, Maozhi Ren1,3,5.
Abstract
Botany-derived antimicrobial peptides (BAMPs), a class of small, cysteine-rich peptides produced in plants, are an important component of the plant immune system. Both in vivo and in vitro experiments have demonstrated their powerful antimicrobial activity. Besides in plants, BAMPs have cross-kingdom applications in human health, with toxic and/or inhibitory effects against a variety of tumor cells and viruses. With their diverse molecular structures, broad-spectrum antimicrobial activity, multiple mechanisms of action, and low cytotoxicity, BAMPs provide ideal backbones for drug design, and are potential candidates for plant protection and disease treatment. Lots of original research has elucidated the properties and antimicrobial mechanisms of BAMPs, and characterized their surface receptors and in vivo targets in pathogens. In this paper, we review and introduce five kinds of representative BAMPs belonging to the pathogenesis-related protein family, dissect their antifungal, antiviral, and anticancer mechanisms, and forecast their prospects in agriculture and global human health. Through the deeper understanding of BAMPs, we provide novel insights for their applications in broad-spectrum and durable plant disease prevention and control, and an outlook on the use of BAMPs in anticancer and antiviral drug design.Entities:
Keywords: botany-derived antimicrobial peptides; disease prevention and control; health security; mechanism of action; molecular targets
Mesh:
Substances:
Year: 2021 PMID: 34768793 PMCID: PMC8583512 DOI: 10.3390/ijms222111363
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Main families of botany-derived antimicrobial peptides (BAMPs) and their modes of action.
| Family | Representative Peptide | Sources | Mode of Action | References |
|---|---|---|---|---|
| Defensin | DmAMP1 |
| DmAMP1 binds to M(IP)2C in the membrane, resulting in potassium efflux, calcium uptake, membrane permeability change, and CWI pathway activation. | [ |
| RsAFP2 |
| RsAFP2 binds to GlcCer in the cell wall and plasma membrane, resulting in ROS production, apoptosis, ion fluxes, and CWI pathway activation. | [ | |
| MsDef1 |
| MsDef1 interacts with GlcCer in the cell wall and membrane, resulting in the activation of MAPK cascade in the CWI pathway, and disruption of Ca2+ signaling and homeostasis, contributing to fungal cell death. | [ | |
| MtDef4 |
| MtDef4 binds to PA and is internalized into the fungal cell, resulting in the disruption of Ca2+ signaling and homeostasis in a different way to MsDef1. An interaction with unknown intracellular targets has been proposed. | [ | |
| NaD1 |
| NaD1 binds to PI(4,5)P2 and dimerizes in the membrane. The dimer is internalized into the cytoplasm and interacts with intracellular targets to trigger the ROS and NO production. | [ | |
| HsAFP1 |
| HsAFP1 binds to the fungal cell wall and plasma membrane via loop 5. It moves into the cytoplasm and targets mitochondria, produces ROS, and induces programmed cell death. | [ | |
| Psd1 |
| Psd1 binds to GlcCer in the plasma membrane. It moves to the cytoplasm and interacts with cyclin F in the nucleus, which results in cell cycle arrest and fungal cell death. | [ | |
| PR1 | PR1a |
| PR1 binds to sterol and sequesters it from pathogens. It inhibits programmed cell death at the pathogen infection sites, and induces the expression of host defense genes by releasing CAPE1 peptide. | [ |
| P14c |
| |||
| Thionins | α1-purothionin |
| Upon application of purothionin, there is a depolarization of the membrane and Ca2+ ion permeability increases. β-purothionin interacts with dimyristoyl-phosphatidylglycerol, and inhibits protein kinase C. | [ |
| Thionin |
| Thionin leads to membrane depolarization, influx of exogenous Ca2+, and activation of PLA2 and adenylate cyclase. | [ | |
| viscotoxins A3 |
| Viscotoxins directly interact with DNA and RNA, interfering with nucleic acid synthesis. | [ | |
| Lipid transfer proteins | Ca-LTP1 |
| Ca-LTP1 penetrates the plasma membrane and causes morphological damage, accompanied by pseudo-mycelia formation. | [ |
| Ha-AP10 |
| Ha-AP10 interacts with phospholipids and produces a direct cytotoxic effect on fungal cells mediated by membrane permeabilization. | [ | |
| Proteinase inhibitor | HyPep |
| HyPep inhibits α-amylase and serine proteinases, and causes cell aggregation and pseudo-mycelia formation. | [ |
Figure 13D structures of BAMPs. (A) Plant defensin from Raphanus sativus (RsAFP2; PDB: 2N2R; Accession: 2N2R_A; pI: 8.70). (B) PR1 from Solanum lycopersicum (P14A; PDB: 1CFE; Accession: 1CFE_A; pI: 8.94). (C) Thionin from Viscum album (Viscotoxin B; PDB: 1JMP; Accession: 1JMP_A; pI: 8.77). (D) Lipid transfer protein from Oryza sativa (nsLTP2; PDB: 1L6H; Accession: 1L6H_A; pI: 8.72). (E) Proteinase-inhibitor from Capsicum annum (HyPep; PDB: 5ZFO; Accession: 5ZFO_A; pI: 6.15). N and C represent N-terminus and C-terminus, respectively. Green represents the amino acid skeleton. Red represents cysteines and disulfide bonds between cysteines.
Figure 2The possible mechanism of BAMPs in antifungal, antiviral, and anticancer activities. (A) The antifungal activity of BAMPs. The antifungal mechanisms of BAMPs are divided into the following categories: (a) BAMPs destroy the membrane permeability through electrostatic interaction with the membrane surface. (b) BAMPs affect membrane structure or in vivo signaling pathways by interacting with lipids such as phospholipids and sphingolipids on fungal membranes. (c) BAMPs interact with fungal cell wall components such as glucan and chitin, thus inhibiting cell wall formation and pathogen growth. (d) BAMPs act on intracellular targets and participate in cellular signaling pathways, including ROS production, programmed cell death, cell cycle arrest, autophagy, the CWI (cell wall integrity) pathway, the MAPK pathway, and so on. (B) The antiviral activity of BAMPs. The replication cycle of the virus during infection is roughly divided into four steps: (a) By recognition and binding to receptors, viruses attach to and fuse with the host membrane. (b) Virus uncoating and release of nucleic acid. (c) Viral genome replication and protein synthesis. (d) Assembly and release of virus particles. During virus replication, BAMPs inhibit virus proliferation and transmission by destroying virus envelope, inhibiting the interaction between capsid proteins with host cell surface receptors, blocking the expression of virus gene, and preventing the assembly and release of virus particles. (C) The anticancer activity of BAMPs. Obvious differences exist in normal and tumor cells, including the charge and receptors on the membrane. On the one hand, BAMPs can especially kill cancer through membrane dissolution; on the other hand, BAMPs regulate angiogenesis, apoptosis, autophagy, cell cycle, and other biological processes which are critical to tumor proliferation and migration after binding to receptors.
Representative botany-derived antimicrobial peptides (BAMPs) with antiviral activity and their modes of action.
| Source of Virus | Representative Peptide | Antiviral Activity | Mode of Action | References |
|---|---|---|---|---|
| Plant virus | StPIP1 | Potato Y virus (PVY) | StPIP1 induces the ROS production, callose deposition, and expression of defense-related genes in plants. | [ |
| A22 and A64 | Tomato Golden Mosaic virus (TGMV) | Peptides interfere with virus replication by binding to the replication origin sequence (OriRep). | [ | |
| AmPep1 | Tomato yellow leaf curl virus (TYLCV) | [ | ||
| Dominant transacting peptide | Tomato chlorotic spot virus (TCSV) | The peptide interacts with the nucleocapsid proteins (N) of different tospoviruses and induces host immune responses. | [ | |
| Animal virus | NTP | Influenza A virus (H1N1) | NTP inhibits virus proliferation by blocking the neuramidase on the virus envelope, and inhibits the cytopathic effect induced by H1N1. | [ |
| Respiratory syncytial virus (RSV) | NTP prevents RSV entry into host cells and proliferation by binding to the viral glycoproteins or inhibiting viral replication and assembly. | |||
| Ginkbilobin | HIV-1 | Peptides suppress the activity of HIV-1 reverse transcriptase. | [ | |
| Ascalin | ||||
| Lunatusin | ||||
| Vulgarinin | ||||
| Meliacine | Foot-and-mouth disease virus (FMDV) | Meliacine prevents the hulling process of FMDV by inhibiting vacuolar acidification, and thus restrains the virus proliferation. | [ | |
| Pep-RTYM | Dengue virus (DENV) | Pep-RTYM binds to the DENV particles to prevent viral interaction with host cell receptors and the subsequent nucleic acid release. | [ |
Representative botany-derived antimicrobial peptides (BAMPs) and some other small peptides with anticancer activity and their modes of action.
| Classification | Representative Peptide | Anticancer Activity | Mode of Action | References |
|---|---|---|---|---|
| BAMPs | Lunasin | Skin, colon, prostate, and breast cancers | Lunasin binds directly to deacetylated histones, inhibits acetylation, and turns off the transcription. | [ |
| Cycloviolacin O2 (CyO2) | Breast cancer and lymphoma cells | CyO2 causes tumor cell death by membrane permeabilization. | [ | |
| MCo-PMI | Adenocarcinoma | MCo-PMI inhibits tumor proliferation by activating the p53 tumor suppressor pathway. | [ | |
| HB7 | Pancreatic cancer | HB7 inhibits the proliferation and migration of tumors by membrane permeabilization. | [ | |
| NaD1 | Monocyte lymphoma | NaD1 inhibits the proliferation of monocyte lymphoma by directly binding to the plasma membrane phosphatidylinositol 4,5-diphosphate. | [ | |
| Viscotoxin B2 | Osteogenic sarcoma | Viscotoxin B2 inhibits tumor cells by membrane lysis. | [ | |
| Ligatoxin B | Lymphoma and adenocarcinoma | Ligatoxin B inhibits the proliferation of tumor cells by inhibiting nucleic acid and protein synthesis. | [ | |
| NTP | Promyelocytic leukemia cells (HL-60) | NTP mediates cancer-related signal transduction cascades by regulating the distribution of lipids in cell membranes, thereby inhibiting tumor cell invasion and metastasis. | [ | |
| Phoratoxins C-F | Different types of solid tumor cells and hematologic tumors | Inhibiting tumor proliferation, while the mechanism of action is unknown. | [ | |
| Thi2.1 | Tumor cells McF-7, A549, and HeLa | [ | ||
| Sesquin | McF-7 and leukemia M1 cells | [ | ||
| Limenin | Leukemia cells | [ | ||
| Purple pole defensin | HepG2, McF-7, and HT-29 cells | [ | ||
| Coccinin | HL60 and L1210 cells | [ | ||
| Other small peptides | Cn-AMP1 | Caco-2 cells | Cn-AMP1 reduces cancer cell viability without causing hemolysis. | [ |
| Cr-ACP | Hep2 cells | Cr-ACP induces cell cycle arrest in G0–G1 phase. | [ | |
| Cherimolacyclopeptide C | KB cells | Cherimolacyclopeptide C shows in vitro cytotoxicity to KB cells. | [ | |
| Cyclosaplin | Breast cancer | Cyclosaplin inhibits cancer cell proliferation in a dose- and time-dependent manner. | [ | |
| Poca A and B | Breast cancer | Poca inhibits cancer cell migration. | [ | |
| IbACP | Panc-1, a pancreatic cancer line | IbACP regulates cellular proliferation by inducing and promoting apoptosis through the mitochondrial apoptotic pathway. | [ | |
| GLTSK | HCT116, human colorectal cancer cells | GLTSK decreases angiotensin II-dependent proliferation in HCT116 through the blockade of the renin-angiotensin system. | [ |
Figure 3The proposed application strategies of BAMPs for agricultural purposes and human health. (A) The application of BAMPs for plant disease control. Plants without or with low BAMPs are vulnerable to fungi and viruses (a), while transgenic expression of BAMPs in vivo or application of BAMPs’ biological agents in vitro can enhance the resistance of host plants to pathogens. Codon optimization (b) and multigene-induced expression (c) can elevate BAMPs expression and broaden host resistance to pathogens. Furthermore, modification of BAMPs in vitro, such as cyclization, can enhance their stability and promote antimicrobial activity, which can be directly used as a biological agent in the future (d). (B) The application of BAMPs for human health. Using fresh-edible plants or chlorella as a bioreactor to prepare oral BAMPs drugs can not only break through the restriction of intravenous injection, but also greatly increase the yield and decrease the cost (e). On the one hand, BAMPs can be biosynthesized in organelles such as vacuoles and chloroplasts to protect them from being degraded by digestive enzymes during oral administration. On the other hand, BAMPs can be directly secreted in the fermentation broth and be prepared for intravenous injection when chlorella is used as a bioreactor. Additionally, N- and/or C-terminus modification of BAMPs can increase their stability and their ability to pass through the biological membrane (f).